Aclaris Therapeutics Inc Total Assets
Aclaris Therapeutics Inc total assets. Based on the latest financial reports, Aclaris Therapeutics Inc (ACRS) holds total assets worth $175.53 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Aclaris Therapeutics Inc (ACRS) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Aclaris Therapeutics Inc (2013–2024)
Total assets of Aclaris Therapeutics Inc from 2013 to 2024. This chart illustrates how Aclaris Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. See Aclaris Therapeutics Inc stock quote for real-time trading data and today's change.
Aclaris Therapeutics Inc - Asset Composition Analysis
Aclaris Therapeutics Inc Total Assets Breakdown (December 2024)
Aclaris Therapeutics Inc total assets breakdown as of December 2024. Aclaris Therapeutics Inc's total assets of $175.53 Million consist of 57.2% current assets and 42.8% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 11.2% |
| Accounts Receivable | $318.00K | 0.1% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Aclaris Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Aclaris Therapeutics Inc (ACRS) liquidity to equity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Aclaris Therapeutics Inc's current assets represent 57.2% of total assets in 2024, a decrease from 94.2% in 2013.
- Cash Position: Cash and equivalents constituted 11.2% of total assets in 2024, down from 67.5% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 0.1% of total assets.
Aclaris Therapeutics Inc Competitors by Total Assets
Key competitors of Aclaris Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
|
USA | $1.26 Billion |
|
Verona Pharma plc
F:I9SA
|
Germany | €572.87 Million |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA
|
USA | $641.76 Million |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
|
China | CN¥37.46 Billion |
|
Metsera, Inc. Common Stock
NASDAQ:MTSR
|
USA | $639.66 Million |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
Bavarian Nordic
CO:BAVA
|
Denmark | Dkr14.95 Billion |
|
Hebei Changshan Biochem Pharma
SHE:300255
|
China | CN¥4.66 Billion |
Aclaris Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.92 | 7.03 | 3.87 |
| Quick Ratio | 3.92 | 7.03 | 3.87 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $74.96 Million | $113.51 Million | $42.62 Million |
Aclaris Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Aclaris Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.88 |
| Latest Market Cap to Assets Ratio | 1.60 |
| Asset Growth Rate (YoY) | 11.6% |
| Total Assets | $220.33 Million |
| Market Capitalization | $353.21 Million USD |
Valuation Analysis
Above Book Valuation: The market values Aclaris Therapeutics Inc's assets above their book value (1.60x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Aclaris Therapeutics Inc's assets grew by 11.6% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Aclaris Therapeutics Inc (2013–2024)
The table below shows the annual total assets of Aclaris Therapeutics Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $220.33 Million | +11.61% |
| 2023-12-31 | $197.41 Million | -22.46% |
| 2022-12-31 | $254.60 Million | +1.35% |
| 2021-12-31 | $251.21 Million | +254.90% |
| 2020-12-31 | $70.78 Million | -27.99% |
| 2019-12-31 | $98.30 Million | -64.33% |
| 2018-12-31 | $275.57 Million | +13.16% |
| 2017-12-31 | $243.51 Million | +38.29% |
| 2016-12-31 | $176.09 Million | +87.17% |
| 2015-12-31 | $94.08 Million | +441.38% |
| 2014-12-31 | $17.38 Million | +22.31% |
| 2013-12-31 | $14.21 Million | -- |
About Aclaris Therapeutics Inc
Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases. Its … Read more